Genticel SA (GTCL)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Genticel SA (GTCL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013240
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Genticel SA (Genticel), formerly BT Pharma, is a biopharmaceutical company that develops therapeutic vaccines for women infected by the human papillomavirus. The company provides pipeline products including ProCervix, a bivalent HPV therapeutic vaccine candidate and multivalent candidate vaccines for patients infected with HPV. It offers technologies such as CyaA vector platform and Vaxiclase for developing products. Genticel also provides clinical trials services. The company’s ProCervix is used for women infected with HPV 16 or HPV 18, before high grade lesions or cervical cancer occur. It operates in Paris and Labege. Genticel is headquartered in Labege, France.

Genticel SA (GTCL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Genticel SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Genticel SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Genticel SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Genticel SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Genticel SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Genticel SA, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Genticel Raises US$23.7 Million In Series C Financing 10
Partnerships 12
Genticel Enters into Agreement with Roche Molecular Systems 12
Merger 13
Genticel Merges with GenKyoTex 13
Licensing Agreements 15
Genticel Enters into Licensing Agreement with Serum Institute of India 15
Equity Offering 16
Genticel Completes IPO For USD47.7 Million 16
Genticel SA – Key Competitors 17
Genticel SA – Key Employees 18
Genticel SA – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Financial Announcements 20
Jan 30, 2017: Genticel Business Update-Fourth Quarter 2016 20
Oct 27, 2016: Genticel: Business Update – Third Quarter 2016 22
Sep 22, 2016: Genticel Presents First Half 2016 Financial Results And Updates Its Operational Outlook 23
Jul 28, 2016: Genticel: Business Update – Second Quarter 2016 26
Mar 14, 2016: Genticel Announces 2015 Annual Results and Strategic Update for 2016 27
Jan 25, 2016: Business Update – Fourth Quarter 2015 30
Corporate Communications 32
Jan 05, 2016: Genticel Appoints Remi Palmantier, PhD, as Chief Scientific Officer to Accelerate Its Development 32
Other Significant Developments 33
Apr 28, 2016: Genticel Provides Business Update – First Quarter 2016 33
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Genticel SA, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Genticel SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Genticel SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Genticel SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Genticel SA, Deals By Therapy Area, 2011 to YTD 2017 8
Genticel SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Genticel Raises US$23.7 Million In Series C Financing 10
Genticel Enters into Agreement with Roche Molecular Systems 12
Genticel Merges with GenKyoTex 13
Genticel Enters into Licensing Agreement with Serum Institute of India 15
Genticel Completes IPO For USD47.7 Million 16
Genticel SA, Key Competitors 17
Genticel SA, Key Employees 18
Genticel SA, Other Locations 19

★海外企業調査レポート[Genticel SA (GTCL)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sandoz International GmbH-製薬・医療分野:企業M&A・提携分析
    Summary Sandoz International GmbH (Sandoz), a subsidiary of Novartis AG develops, manufactures and commercializes generic pharmaceutical products. The company provides biosimilars, generic antibiotics, dermatology and transplantation medicines. Its biosimilars comprise Omnitrope, Binocrit and Zarzio …
  • Fujifilm Holdings Corp (FUJIY):企業の財務・戦略的SWOT分析
    Fujifilm Holdings Corp (FUJIY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Shinko Electric Industries Co., Ltd.:企業の戦略・SWOT・財務情報
    Shinko Electric Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shinko Electric Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Weifa ASA (WEIFA)-製薬・医療分野:企業M&A・提携分析
    Summary Weifa ASA (Weifa), formerly Aqualis ASA, is a pharmaceutical company that conducts the research and development, manufacture, distribution and sales of pharmaceutical products, lifestyle products and solutions. The company has over the counter (OTC) pharmaceutical market in Norway offering p …
  • Stiefel Laboratories Inc-製薬・医療分野:企業M&A・提携分析
    Summary Stiefel Laboratories Inc (Stiefel Laboratories), a subsidiary of GlaxoSmithKline Plc is a healthcare products provider that develops products for sun care, dry skin and clear skin. The company also offers research and development, manufacture, marketing and distribution of prescription medic …
  • Grupo Nutresa SA (NUTRESA):企業の財務・戦略的SWOT分析
    Grupo Nutresa SA (NUTRESA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Genome Institute of Singapore:製薬・医療:M&Aディール及び事業提携情報
    Summary Genome Institute of Singapore (GIS) is a research institute that provides research programs and services in different areas. The institute concentrates on genomic sciences to improve public health and prosperity in Singapore. It operates technology and comprises early career researchers such …
  • Qsc AG (QSC):企業の財務・戦略的SWOT分析
    Summary Qsc AG (Qsc) is a telecommunication company that provides integrated telecommunication and managed services. The company offers services such as cloud and IT outsourcing, Internet of Things services, sap services and consulting, broadband and network services, and colocation services. Its cl …
  • HeartSciences:医療機器:M&Aディール及び事業提携情報
    Summary HeartSciences, formerly Heart Test Laboratories Inc, is a medical device company that offers cardiac care products. The company develops, manufactures and markets cardiac testing tools for the early detection of heart disease. It offers MyoVista, a screening tool used to determine the presen …
  • Kuraray Co Ltd (3405):企業の財務・戦略的SWOT分析
    Kuraray Co Ltd (3405) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • The Hackett Group, Inc. (HCKT):企業の財務・戦略的SWOT分析
    The Hackett Group, Inc. (HCKT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Morphotek Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Morphotek Inc (Morphotek), a subsidiary of Eisai Inc, is a clinical-stage biotechnology company that develops monoclonal antibodies, antibody drug conjugates, and bispecific antibodies to treat cancer, inflammatory and infectious diseases. Its pipeline product portfolio includes farletuzumab …
  • University of Aberdeen:製薬・医療:M&Aディール及び事業提携情報
    Summary University of Aberdeen (UOA) is an educational and research institution that offers educational and research programs. The university offers undergraduate, graduate, postgraduate and research programs. It provides undergraduate and postgraduate courses in the areas of education, creative art …
  • Oxtex Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Oxtex Ltd (Oxtex), formerly Oxtexs Ltd is a medical device company that offers novel self inflating tissue expansion and medical devices. The company’s products include implantable self-inflating tissue expanders that are suitable for specific needs of the clinician and the patient. It uses …
  • Caixa Geral de Depositos SA:企業の戦略的SWOT分析
    Caixa Geral de Depositos SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • National Company KazMunayGas:石油・ガス:M&Aディール及び事業提携情報
    Summary National Company KazMunayGas (KazMunayGas) is a state-owned, vertically integrated oil and gas company. It carries out the acquisition, exploration, development, production, processing, transportation, refining and export of hydrocarbons. The company also produces petrochemicals, stores and …
  • Batu Biologics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Batu Biologics Inc (Batu Biologics) is a biotechnology based pharmaceutical company which develops and commercializes novel cell and gene therapies. Its lead product, ValloVax, a cellular anti-angiogenic cancer vaccine, is developed to induce an immune response against the tumor endothelium …
  • North Asia Strategic Holdings Limited
    North Asia Strategic Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary North Asia Strategic Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • PriceSmart, Inc.:企業の戦略・SWOT・財務分析
    PriceSmart, Inc. - Strategy, SWOT and Corporate Finance Report Summary PriceSmart, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Enel SpA (ENEL):電力:M&Aディール及び事業提携情報
    Summary Enel SpA (Enel) is an integrated electricity and gas company that produces, distributes and trades electricity and natural gas. The group generates electricity using diverse sources of energy such as nuclear, renewables, oil and gas turbine, coal and gas combined cycle. It also focuses on di …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆